The NCCN Guidelines for Lung Cancer Screening have played a significant role in shaping clinical practice and policy, leading to increased coverage for lung cancer screening, increased incidence of early-stage disease, decreased incidence of late
Search Results
Screening for Lung Cancer: An Expert Review
Presented by: Ella A. Kazerooni, Jacob Sands, and Douglas E. Wood
HSR24-155: Disparities in Real-World Screening Mammography Compliance Rates by Body Mass Index and Mobility-Restricting Diagnosis—A Commercial Claims-Based Analysis
Julia Olsen, Scott Pohlman, and Jason Shames
Background: Screening mammography plays a key role in early breast cancer detection. This population-based claims analysis examines screening mammography compliance rates in populations prone to limitations or challenges with positioning during
Prostate Cancer
James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski, and Patrick C. Walsh
cancer in men. 1 Experts generally believe that these changes resulted from prostate-specific antigen (PSA) screening that detected many early-stage prostate cancers. For example, the percentage of patients with low-risk disease has increased (45.3% in
Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer
Camilla Zimmermann, Ashley Pope, Breffni Hannon, Monika K. Krzyzanowska, Gary Rodin, Madeline Li, Doris Howell, Jennifer J. Knox, Natasha B. Leighl, Srikala Sridhar, Amit M. Oza, Rebecca Prince, Stephanie Lheureux, Aaron R. Hansen, Anne Rydall, Brittany Chow, Leonie Herx, Christopher M. Booth, Deborah Dudgeon, Neesha Dhani, Geoffrey Liu, Philippe L. Bedard, Jean Mathews, Nadia Swami, and Lisa W. Le
of distress screening with linked interventions 23 – 26 ; however, none have coupled symptom screening with an EPC intervention. The primary aim of this single-arm phase II trial was to assess the feasibility of a novel intervention
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020
Featured Updates to the NCCN Guidelines
Dawn Provenzale, Reid M. Ness, Xavier Llor, Jennifer M. Weiss, Benjamin Abbadessa, Gregory Cooper, Dayna S. Early, Mark Friedman, Francis M. Giardiello, Kathryn Glaser, Suryakanth Gurudu, Amy L. Halverson, Rachel Issaka, Rishi Jain, Priyanka Kanth, Trilokesh Kidambi, Audrey J. Lazenby, Lillias Maguire, Arnold J. Markowitz, Folasade P. May, Robert J. Mayer, Shivan Mehta, Swati Patel, Shajan Peter, Peter P. Stanich, Jonathan Terdiman, Jennifer Keller, Mary A. Dwyer, and Ndiya Ogba
be able to: Integrate into professional practice the updates to the NCCN Guidelines for Colorectal Cancer Screening Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Colorectal Cancer Screening Disclosure
Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position
Mark A. Helvie and Therese B. Bevers
Recognizing that the purpose of breast cancer screening is to decrease breast cancer mortality and morbidity, NCCN continues to recommend annual screening mammography beginning at age 40 years for average-risk women. Mammographic screening and
Screening and Stepped Care Targeting Psychological Distress in Patients With Metastatic Colorectal Cancer: The TES Cluster Randomized Trial
Claudia S.E.W. Schuurhuizen, Annemarie M.J. Braamse, Aartjan T.F. Beekman, Pim Cuijpers, Mecheline H.M. van der Linden, Adriaan W. Hoogendoorn, Hans Berkhof, Dirkje W. Sommeijer, Vera Lustig, Suzan Vrijaldenhoven, Haiko J. Bloemendal, Cees J. van Groeningen, Annette A. van Zweeden, Maurice J.D.L. van der Vorst, Ron Rietbroek, Cathrien S. Tromp-van Driel, Machteld N.W. Wymenga, Peter W. van der Linden, Aart Beeker, Marco B. Polee, Erdogan Batman, Maartje Los, Aart van Bochove, Jan A.C. Brakenhoff, Inge R.H.M. Konings, Henk M.W. Verheul, and Joost Dekker
screening for distress is recommended by a number of major cancer organizations, with the assumption that identification of elevated levels of distress will result in increased uptake of psychosocial services and reduction in distress. 2 , 6 Psychosocial
Use of NCCN Guidelines, Other Guidelines, and Biomarkers for Colorectal Cancer Screening
Christina D. Williams, William M. Grady, and Leah L. Zullig
-related deaths are expected. 1 Despite the considerable public health burden of CRC, incidence and mortality rates have significantly declined in the past few decades; this trend is mainly attributed to treatment innovations and increased CRC screening. 1 – 3
BPI19-018: Cancer Screening Rates and Adherence of Uninsured Cancer Patients in Free Clinics
Katherine Robinson, Amber Todd, Abu-Sayeef Mirza, Madeline Macdonald, Noura Ayoubi, Rahul Mhaskar, Richard Roetzheim, Laurie Woodard, and Smitha Pabbathi
Background: There are limited studies documenting the prevalence of malignancies and the cancer screening practices of the uninsured population. Cancer survivors require continued cancer surveillance and screening for recurrence and second
The Case for Tailored Prostate Cancer Screening: An NCCN Perspective
Michelle L. McDonald and J. Kellogg Parsons
efficacy of PSA population screening to diminish prostate cancer mortality ( Table 1 ). Nevertheless, aggressive screening, diagnosis, and treatment of prostate cancer has generated debate regarding overdetection. 5 Overdetection is the diagnosis of
